Wound Care Biologics Market by Product [Cellular and/or tissue-based products (Keratinocytes, Fibroblasts, Adipose-derived stromal cells, and others), Biologic Skin Substitutes (Acellular Products, Cellular Products, Biosynthetic Products, and Others), Topical Agents, Growth Factors (Recombinant human platelet-derived growth factor-BB, Keratinocyte growth factor, Recombinant human epidermal growth factor, and Others), Scaffolds, and Others], Wound Type [Ulcers (Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers, and Others), Traumatic Wounds, Burns, Post-operative incisions, Abrasions, Cuts And Lacerations, Skin Irritations, Conditions with Periostomal Care, and Others], Application (Hydrogels, Film Dressings, Nanofiber-Based Dressings, Extracellular matrix-derived biomaterials, and Others), End User (Hospitals, ASCs, Burn Centers and Wound Clinics, and Others): Global Market Size Estimates and Forecast (2022-2030)

Code: BMIRE00026034 | Pages: 100 | Industry: Pharmaceuticals | Date: Sep 2022 | Type: Global

The market crossed US$ 2.0 billion mark in 2022 and is expected to hit US$ 3.23 billion by 2030, recording a CAGR of 6.1% during the forecast period. 

Rising incidences of burn injuries has aided the overall would care biologics market.

Rising incidences of burn injuries, specifically in developing and underdeveloped countries has positively impacted the wound care biologics industry growth at present and is expected to continue a similar trend over the forecast period. Countries such as Africa and Brazil have a high number of burn cases. According to World Health Organization (WHO), approximately 180,000 deaths are caused due to burns in low- and middle-income countries annually. Burns not only have a high economic impact but also have disastrous effects on the victim’s skin. Chronic skin wounds can be caused due to burns, skin cancers, infections, trauma or an underlying medical condition such as diabetes. With the growing prevalence of these ailments along with the expanding geriatric population, there has been a rise in the demand for treatments that can accelerate wound healing and facilitate a speedy recovery.

Within the report, the market is segmented into product, wound type, application, user, and geography. By product type, the market is segmented into cellular and/or tissue-based products (keratinocytes, fibroblasts, adipose-derived stromal cells, others), biologic skin substitutes(acellular products, cellular products, biosynthetic products, others), topical agents, growth factors(recombinant human platelet-derived growth factor-bb (RHPDGF-bb), keratinocyte growth factor (KGF), recombinant human epidermal growth factor (rh s), others), scaffolds, and others. On the basis of wound type, the market is segmented into ulcers, traumatic wounds, burns, post-operative incisions, abrasions, cuts and lacerations, skin irritations, conditions with periostomal care, others. Ulcers is further segmented into diabetic foot ulcers, venous ulcers, pressure ulcers, others. By application, the market is categorized into hydrogels, film dressings, nanofiber-based dressings, extracellular matrix-derived biomaterials, others. Based on end user, the market is divided into hospitals, ambulatory surgical centers, burn centers and wound clinics, and others. Geographically, the market is subsegmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.

Asia Pacific market to exhibit fastest growth over the forecast period.

Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections. Wound healing is a complex process involving inflammation, accumulation of fibrous tissue, deposition of collagen, formation of epithelial cell layers, and other disruptions. Biologic wound healing treatments possess the ability to restore the natural repair mechanism through active biological agents. For instance, plant-derived active biomolecules with antimicrobial, anti-inflammatory, or antioxidant properties have proven efficacious in advancing the wound-healing process. Some of the recent technological advancements made in the field of wound healing include skin substitutes, bio-membranes, scaffolds, hydroconductive dressings, and biologics. Asia Pacific is expected to exhibit the highest growth in the global wound care biologics market over the forecast period. This is owing to the high prevalence of diabetic patients in Asian countries. According to the Indian Diabetes Research Foundation, in 2021, around 60% of the world’s population suffering from diabetes lived in Asia, with around one-half in China and India combined. The Foundation also states that Western Pacific reported over 138.2 million people suffering from diabetes, the number for which is expected to rise to 201.8 million by 2035.

Hydrogels segment captured the largest share in 2022.

Hydrogel dressings are three-dimensional networks of hydrophilic polymers. They provide a moist environment in the wound site which promotes tissue regeneration by granulation and re-epithelialization. Hydrogel dressings have been conveniently used for the treatment of chronic wounds. Compared to other chronic wound treatment strategies, the properties of hydrogel-based dressings can easily be modified. Due to their flexible and tunable properties, hydrogel dressings can easily obtain additional functional properties by loading cells, antibacterial, antiviral, and antifungal agents, growth factors, and biomolecules to speed up wound contraction and healing. Hydrogel dressings can be developed for specific wounds based on their severity, size, and location. Hydrogels have great potential to present multi-functional properties. Different aspects, such as biocompatibility, biodegradability, adhesiveness, vascularization potential, as well as antimicrobial, anti-inflammatory, and pro-angiogenic properties, can be incorporated into hydrogels for chronic wound healing. Popular choices for antimicrobial hydrogel wound care commonly include Triad, SilvaSorb, MANUKApli Sterile Honey Wound Dressing, and Anasept 

Get more information on this report :

Recent strategic developments in wound care biologics market

The wound care biologics market has undergone several significant developments, and a few of these have been mentioned below:

  • In June 2021, MIMEDX (US) received approval from the Japanese Ministry of Health, Labour and Welfare for the commercialization of Epifix in Japan.
  • In April 2021, Kerecis (Iceland) launched its Kerecis Omega3 GraftGuide, an intact fish skin that uniquely addresses the challenges of burn healing.
  • In January 2021, Integra LifeSciences (US) acquired ACell, Inc. (US). This acquisition enabled Integra to provide more comprehensive and complex wound management solutions.
  • In November 2020, Stryker Corporation (US) acquired Wright Medical Group N.V. (Netherlands), a global medical devices company focused on extremities and biologics.

The wound care biologics market is driven by several players by implementing strategic activities such as investments, new launches, mergers & acquisitions, and partnerships. Smith & Nephew plc., Organogenesis Inc., MIMEDX, Integra LifeSciences, Stryker Corporation, Bioventus LLC., AbbVie Inc., Kerecis, Merakris Therapeutics, Medline Industries, LP, Skye Biologics Holdings, LLC are among the prominent players operating in the market.

Target audience for the report:

  • Distributors of Wound Care Biologics
  • Biopharmaceutical Companies
  • Urgent Care Centers
  • Clinics
  • Hospitals
  • Burn Care Centers
  • Healthcare Consultants

Scope of the report:

In this report, the market has been segmented on the basis of:

  • Product:
    • Cellular and/or tissue-based products (CTPs)
      • Keratinocytes
      • Fibroblasts
      • Adipose-derived stromal cells
      • Others
    • Biologic Skin Substitutes
      • Acellular Products
      • Cellular Products
      • Biosynthetic Products
      • Others
    • Topical Agents
    • Growth Factors
      • Recombinant human platelet-derived growth factor-BB (rhPDGF-BB)
      • Keratinocyte growth factor (KGF)
      • Recombinant human epidermal growth factor (rh EGF)
      • Others
    • Scaffolds
    • Others

 

  • Wound Type
    • Ulcers
      • Diabetic Foot Ulcers
      • Venous Ulcers
      • Pressure Ulcers
      • Others
    • Traumatic Wounds
    • Burns
    • Post-operative incisions
    • Abrasions, cuts and lacerations
    • Skin irritations
    • Conditions with periostomal care
    • Others
  • Application:
    • Hydrogels
    • Film Dressings
    • Nanofiber-Based Dressings
    • Extracellular matrix-derived biomaterials
    • Others
  • End User:
    • Hospitals
    • ASCs
    • Burn Centers and Wound Clinics
    • Others
  • Region
    • North America
    • Europe
    • Asia Pacific
    • South & Central America
    • Middle East & Africa
  • Companies profiled
    • Smith & Nephew plc.
    • Organogenesis Inc.
    • MIMEDX
    • Integra LifeSciences
    • Stryker Corporation
    • Bioventus LLC.
    • AbbVie Inc.
    • Kerecis
    • Merakris Therapeutics
    • Medline Industries, LP
    • Skye Biologics Holdings, LLC

Companies profiled
- Smith & Nephew plc.
- Organogenesis Inc.
- MIMEDX
- Integra LifeSciences
- Stryker Corporation
- Bioventus LLC.
- AbbVie Inc.
- Kerecis
- Merakris Therapeutics
- Medline Industries, LP
- Skye Biologics Holdings, LLC

Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$1500
Site License
$2500
Enterprise License
$3500